In breast cancer, CD133 expression has been associated with poor overall survival probability, high tumour grade, lymph node metastasis, hormone receptor negativity, and HER2 positivity, as well as advanced tumours, nodes, and metastasis (TNM) stage [91]. The gene discussed is ERBB2; the disease is breast carcinoma.